Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Inhibition of Sphingosine Phosphate Receptor 1 Signaling Enhances the Efficacy of VEGF Receptor Inhibition.

Fischl AS, Wang X, Falcon BL, Almonte-Baldonado R, Bodenmiller D, Evans G, Stewart J, Wilson T, Hipskind P, Manro J, Uhlik MT, Chintharlapalli S, Gerald D, Alsop DC, Benjamin LE, Bhatt RS.

Mol Cancer Ther. 2019 Apr;18(4):856-867. doi: 10.1158/1535-7163.MCT-18-0548. Epub 2019 Feb 20.

2.

Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors.

Konicek BW, Capen AR, Credille KM, Ebert PJ, Falcon BL, Heady GL, Patel BKR, Peek VL, Stephens JR, Stewart JA, Stout SL, Timm DE, Um SL, Willard MD, Wulur IH, Zeng Y, Wang Y, Walgren RA, Betty Yan SC.

Oncotarget. 2018 Feb 13;9(17):13796-13806. doi: 10.18632/oncotarget.24488. eCollection 2018 Mar 2.

3.

The Checkpoint Kinase 1 Inhibitor Prexasertib Induces Regression of Preclinical Models of Human Neuroblastoma.

Lowery CD, VanWye AB, Dowless M, Blosser W, Falcon BL, Stewart J, Stephens J, Beckmann RP, Bence Lin A, Stancato LF.

Clin Cancer Res. 2017 Aug 1;23(15):4354-4363. doi: 10.1158/1078-0432.CCR-16-2876. Epub 2017 Mar 7.

4.

Antagonist antibodies to vascular endothelial growth factor receptor 2 (VEGFR-2) as anti-angiogenic agents.

Falcon BL, Chintharlapalli S, Uhlik MT, Pytowski B.

Pharmacol Ther. 2016 Aug;164:204-25. doi: 10.1016/j.pharmthera.2016.06.001. Epub 2016 Jun 8. Review.

5.

Stromal-Based Signatures for the Classification of Gastric Cancer.

Uhlik MT, Liu J, Falcon BL, Iyer S, Stewart J, Celikkaya H, O'Mahony M, Sevinsky C, Lowes C, Douglass L, Jeffries C, Bodenmiller D, Chintharlapalli S, Fischl A, Gerald D, Xue Q, Lee JY, Santamaria-Pang A, Al-Kofahi Y, Sui Y, Desai K, Doman T, Aggarwal A, Carter JH, Pytowski B, Jaminet SC, Ginty F, Nasir A, Nagy JA, Dvorak HF, Benjamin LE.

Cancer Res. 2016 May 1;76(9):2573-86. doi: 10.1158/0008-5472.CAN-16-0022.

6.

An in vitro cord formation assay identifies unique vascular phenotypes associated with angiogenic growth factors.

Falcon BL, Swearingen M, Gough WH, Lee L, Foreman R, Uhlik M, Hanson JC, Lee JA, McClure DB, Chintharlapalli S.

PLoS One. 2014 Sep 11;9(9):e106901. doi: 10.1371/journal.pone.0106901. eCollection 2014.

7.

Development and characterization of a high-throughput in vitro cord formation model insensitive to VEGF inhibition.

Falcon BL, O'Clair B, McClure D, Evans GF, Stewart J, Swearingen ML, Chen Y, Allard K, Lee LN, Neote K, McEwen DP, Uhlik MT, Chintharlapalli S.

J Hematol Oncol. 2013 Apr 27;6:31. doi: 10.1186/1756-8722-6-31.

8.

High-content multiplexed tissue imaging and quantification for cancer drug discovery.

Falcon BL, Stewart J, Ezell S, Hanson J, Wijsman J, Ye X, Westin E, Donoho G, Credille K, Uhlik MT.

Drug Discov Today. 2013 Jun;18(11-12):510-22. doi: 10.1016/j.drudis.2012.08.008. Epub 2012 Sep 1. Review.

PMID:
22944609
9.

Increased vascular delivery and efficacy of chemotherapy after inhibition of platelet-derived growth factor-B.

Falcon BL, Pietras K, Chou J, Chen D, Sennino B, Hanahan D, McDonald DM.

Am J Pathol. 2011 Jun;178(6):2920-30. doi: 10.1016/j.ajpath.2011.02.019.

10.

Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1/mTORC2 inhibitors.

Falcon BL, Barr S, Gokhale PC, Chou J, Fogarty J, Depeille P, Miglarese M, Epstein DM, McDonald DM.

Cancer Res. 2011 Mar 1;71(5):1573-83. doi: 10.1158/0008-5472.CAN-10-3126.

11.

Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody.

Coxon A, Bready J, Min H, Kaufman S, Leal J, Yu D, Lee TA, Sun JR, Estrada J, Bolon B, McCabe J, Wang L, Rex K, Caenepeel S, Hughes P, Cordover D, Kim H, Han SJ, Michaels ML, Hsu E, Shimamoto G, Cattley R, Hurh E, Nguyen L, Wang SX, Ndifor A, Hayward IJ, Falcón BL, McDonald DM, Li L, Boone T, Kendall R, Radinsky R, Oliner JD.

Mol Cancer Ther. 2010 Oct;9(10):2641-51. doi: 10.1158/1535-7163.MCT-10-0213.

12.

Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth.

Hashizume H, Falcón BL, Kuroda T, Baluk P, Coxon A, Yu D, Bready JV, Oliner JD, McDonald DM.

Cancer Res. 2010 Mar 15;70(6):2213-23. doi: 10.1158/0008-5472.CAN-09-1977. Epub 2010 Mar 2.

13.

Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels.

Falcón BL, Hashizume H, Koumoutsakos P, Chou J, Bready JV, Coxon A, Oliner JD, McDonald DM.

Am J Pathol. 2009 Nov;175(5):2159-70. doi: 10.2353/ajpath.2009.090391. Epub 2009 Oct 8.

14.

Sequential loss of tumor vessel pericytes and endothelial cells after inhibition of platelet-derived growth factor B by selective aptamer AX102.

Sennino B, Falcón BL, McCauley D, Le T, McCauley T, Kurz JC, Haskell A, Epstein DM, McDonald DM.

Cancer Res. 2007 Aug 1;67(15):7358-67.

15.

Angiotensin II type 2 receptor-mediated gene expression profiling in human coronary artery endothelial cells.

Falcón BL, Veerasingham SJ, Sumners C, Raizada MK.

Hypertension. 2005 Apr;45(4):692-7. Epub 2005 Feb 14.

PMID:
15710780
16.

Angiotensin II type 2 receptor gene transfer elicits cardioprotective effects in an angiotensin II infusion rat model of hypertension.

Falcón BL, Stewart JM, Bourassa E, Katovich MJ, Walter G, Speth RC, Sumners C, Raizada MK.

Physiol Genomics. 2004 Nov 17;19(3):255-61. Epub 2004 Sep 21.

PMID:
15383639

Supplemental Content

Loading ...
Support Center